Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005853 · ClinicalTrials.gov registry record · Phase 2
Biological Therapy in Treating Patients With Myelodysplastic Syndrome
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005853 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center.
The verdict
NCT00005853, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of biological therapy in treating patients who have myelodysplastic syndrome.
Interventions
- BIOLOGICAL anti-thymocyte globulin
- BIOLOGICAL etanercept
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-12 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005853
The ClinicalTrials.gov registry entry for NCT00005853 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which anti-thymocyte globulin is the first listed.
NCT00005853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005853 about?
NCT00005853 is a clinical study titled "Biological Therapy in Treating Patients With Myelodysplastic Syndrome". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of biological therapy in treating patients who have ...
What is the current status of trial NCT00005853?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-12. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00005853?
The interventions under investigation include: anti-thymocyte globulin (BIOLOGICAL), etanercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005853?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.